| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Giselle F Taboada, Ines Donangelo, Renata F C Guimarães, Mariangélica de O Silva, Rosita Fontes, Mônica R Gadelh. [Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR]. Arquivos brasileiros de endocrinologia e metabologia. vol 49. issue 3. 2006-09-28. PMID:16543993. |
somatostatin analogues are frequently used to treat acromegaly. |
2006-09-28 |
2023-08-12 |
Not clear |
| M G Burt, K K Y H. Newer options in the management of acromegaly. Internal medicine journal. vol 36. issue 7. 2006-09-14. PMID:16780450. |
surgery and radiotherapy were the mainstay of acromegaly management before the advent of the effective pharmacological therapies of the modern era: somatostatin analogues and pegvisomant, a growth hormone receptor antagonist. |
2006-09-14 |
2023-08-12 |
Not clear |
| B Steffin, B Gutt, M Bidlingmaier, C Dieterle, F Oltmann, J Schopoh. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. European journal of endocrinology. vol 155. issue 1. 2006-08-23. PMID:16793952. |
effects of the long-acting somatostatin analogue lanreotide autogel on glucose tolerance and insulin resistance in acromegaly. |
2006-08-23 |
2023-08-12 |
Not clear |
| Marco Losa, Pietro Mortini, Laura Urbaz, Paolo Ribotto, Tristana Castrignanó, Massimo Giovanell. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. Journal of neurosurgery. vol 104. issue 6. 2006-07-18. PMID:16776333. |
presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. |
2006-07-18 |
2023-08-12 |
Not clear |
| Marco Losa, Pietro Mortini, Laura Urbaz, Paolo Ribotto, Tristana Castrignanó, Massimo Giovanell. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. Journal of neurosurgery. vol 104. issue 6. 2006-07-18. PMID:16776333. |
the question of whether preoperative therapy with somatostatin analogs can improve surgical outcome in acromegaly has not been definitively answered. |
2006-07-18 |
2023-08-12 |
Not clear |
| Marco Losa, Pietro Mortini, Laura Urbaz, Paolo Ribotto, Tristana Castrignanó, Massimo Giovanell. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. Journal of neurosurgery. vol 104. issue 6. 2006-07-18. PMID:16776333. |
in this paper, the authors report the effects of preoperative treatment with somatostatin analogs in a large sample of patients with acromegaly. |
2006-07-18 |
2023-08-12 |
Not clear |
| Linda J Woodhouse, Annice Mukherjee, Stephen M Shalet, Shereen Ezza. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocrine reviews. vol 27. issue 3. 2006-07-06. PMID:16543384. |
the availability of recombinant human gh and somatostatin analogs has resulted in widespread treatment for adults with gh deficiency (ghd) and those with gh excess (acromegaly). |
2006-07-06 |
2023-08-12 |
human |
| Annamaria Colao, Rosario Pivonello, Renata S Auriemma, Francesco Briganti, Mariano Galdiero, Fabio Tortora, Ferdinando Caranci, Sossio Cirillo, Gaetano Lombard. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. The Journal of clinical endocrinology and metabolism. vol 91. issue 6. 2006-06-29. PMID:16537687. |
predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. |
2006-06-29 |
2023-08-12 |
Not clear |
| Sarantis Livadas, Dimitrios J Hadjidakis, Maria I Argyropoulou, Maria Stamatelatou, Dimitrios Kelekis, Sotirios A Rapti. Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Hormones (Athens, Greece). vol 5. issue 1. 2006-06-23. PMID:16728386. |
the use of somatostatin analogues as primary or adjunctive therapy has been widely applied in the management of acromegaly. |
2006-06-23 |
2023-08-12 |
Not clear |
| Nienke R Biermasz, Johannes A Romijn, Alberto M Pereira, Ferdinand Roelfsem. Current pharmacotherapy for acromegaly: a review. Expert opinion on pharmacotherapy. vol 6. issue 14. 2006-06-16. PMID:16259571. |
this review focuses on the treatment options for acromegaly (e.g., surgery, radiotherapy and pharmacotherapy with the depot preparations of the somatostatin analogues octreotide long-acting release formulation, lanreotide slow-release formulation and lanreotide autogel, the growth hormone antagonist pegvisomant and the dopamine agonist cabergoline). |
2006-06-16 |
2023-08-12 |
Not clear |
| S Petersen. Efficacy and limits of somatostatin analogs. Journal of endocrinological investigation. vol 28. issue 11 Suppl International. 2006-06-12. PMID:16625846. |
for a considerable time, somatostatin analogs have been the medical therapy of choice for the treatment of acromegaly. |
2006-06-12 |
2023-08-12 |
Not clear |
| S Petersen. Efficacy and limits of somatostatin analogs. Journal of endocrinological investigation. vol 28. issue 11 Suppl International. 2006-06-12. PMID:16625846. |
regarding primary treatment of acromegaly with long-acting somatostatin analogs, our review of five published studies, that applied stringent criteria for the analysis of biochemical normalization, revealed sufficient gh and igf-i suppression in 68% and 61% of the 107 patients included, respectively, and significant tumor reduction in 51%. |
2006-06-12 |
2023-08-12 |
Not clear |
| S Petersen. Efficacy and limits of somatostatin analogs. Journal of endocrinological investigation. vol 28. issue 11 Suppl International. 2006-06-12. PMID:16625846. |
therefore, somatostatin analogs represent an effective medical therapy in a significant proportion of patients with acromegaly. |
2006-06-12 |
2023-08-12 |
Not clear |
| S Petersen. Efficacy and limits of somatostatin analogs. Journal of endocrinological investigation. vol 28. issue 11 Suppl International. 2006-06-12. PMID:16625846. |
new somatostatin receptor ligands with extended binding profile may have even higher efficacy in the biochemical control of patients with acromegaly. |
2006-06-12 |
2023-08-12 |
Not clear |
| A Colao, R Pivonello, R S Auriemma, M Galdiero, E Guerra, F Milone, M De Leo, G Lombard. New perspectives in the medical treatment of acromegaly. Journal of endocrinological investigation. vol 28. issue 11 Suppl International. 2006-06-12. PMID:16625847. |
currently available medical treatment of acromegaly includes dopamine agonists, slow release formulation of somatostatin analogues and pegvisomant, a gh-receptor antagonist. |
2006-06-12 |
2023-08-12 |
Not clear |
| A Colao, R Pivonello, R S Auriemma, M Galdiero, E Guerra, F Milone, M De Leo, G Lombard. New perspectives in the medical treatment of acromegaly. Journal of endocrinological investigation. vol 28. issue 11 Suppl International. 2006-06-12. PMID:16625847. |
in a preliminary study in patients with acromegaly, a new somatostatin analogue with affinity to four of the five somatostatin receptors (som230) was shown to be similarly effective as octreotide in some patients and more effective than octreotide in other patients. |
2006-06-12 |
2023-08-12 |
Not clear |
| Weifeng Ruan, Fabian Fahlbusch, David R Clemmons, Marie E Monaco, Paul D Walden, Antonio P Silva, Herbert A Schmid, David L Kleinber. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Molecular endocrinology (Baltimore, Md.). vol 20. issue 2. 2006-05-18. PMID:16223973. |
somatostatin analogs (sas) treat acromegaly by lowering pituitary gh secretion, which, in turn, lowers systemic igf-i. |
2006-05-18 |
2023-08-12 |
rat |
| Mary Lee Vance, Edward R Law. Role of medical therapy in the management of acromegaly. Neurosurgery. vol 56. issue 5. 2006-05-04. PMID:15854234. |
somatostatin analogs have been the mainstay of medical therapy for acromegaly. |
2006-05-04 |
2023-08-12 |
Not clear |
| Annamaria Colao, Rosario Pivonello, Renata S Auriemma, Maria Cristina De Martino, Martin Bidlingmaier, Francesco Briganti, Fabio Tortora, Pia Burman, Ione A Kourides, Christian J Strasburger, Gaetano Lombard. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European journal of endocrinology. vol 154. issue 3. 2006-04-20. PMID:16498061. |
efficacy of 12-month treatment with the gh receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on igf-i levels, tumor mass, hypertension and glucose tolerance. |
2006-04-20 |
2023-08-12 |
Not clear |
| M Gola, S Bonadonna, G Mazziotti, G Amato, A Giustin. Resistance to somatostatin analogs in acromegaly: an evolving concept? Journal of endocrinological investigation. vol 29. issue 1. 2006-04-14. PMID:16553040. |
resistance to somatostatin analogs in acromegaly: an evolving concept? |
2006-04-14 |
2023-08-12 |
Not clear |